MBRX

Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company focused on developing therapeutic candidates for hard-to-treat tumors and viral infections. Its lead program, Annamycin, is a next-generation anthracycline aimed at treating relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases, designed to overcome multidrug resistance and reduce cardiotoxicity. The company is also developing WP1066, an immune/transcription modulator for various cancers, and a portfolio of antimetabolites, including WP1122, targeting both viral infections and cancer.